Abbvie Inc.

Scuola Internazionale Superiore Di Studi Avanzati

Abbott Research B.v.

Medical Research Council

Lay Line Genomics S.p.a.

Mrc Sissa-scuola Internazionale Superiore De Studi Avanzati

Antonino Cattaneo

Doriano Lamba

Sonia Covaceuszach

Flaminia Pavone

Michela Visintin

Gabriele Ugolini

Sara Marinelli

Wai-Choi Eric Tse

Terence Rabbits

Amos Maritan

Terrence Rabbitts

Giovanni Settanni

Simona Capsoni

Sara Martinelli

Francesca Ruberti

Use of an anti-NGF antibody capable of inhibiting the binding between NGF and TrkA, capable of blocking the biological activity of TrkA for the preparation of a medicament for treating and/or preventing chronic pain.

Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect

Method for the humanization of the VH and VL variable regions of an animal antibody of known sequence, humanized animal antibody obtainable according to the method, in particular anti-NGF and anti-TrkA humanized animal antibodies.

Polynucleotides encoding humanized anti-NGF antibodies

Method for the treatment of pain with humanized anti-nerve growth factor antibodies

Humanized anti-nerve growth factor antibodies

According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one opioid analgesic for the preparation of a medicament for treating and/or preventing pain.

Method for the potentiation of opioid analgesics effects on pain

A general immunoglobulin-target assay system is provided, in which a positive outcome (the generation of a signal) depends only on the intracellular interaction of immunoglobulin with target. This can be accomplished for many immunoglobulins expressed in yeast and/or in mammalian cells and allows the selection of immunoglobulins which are capable of functioning in an intracellular environment.

Selection of intracellular immunoglobulins

A method of identifying at least one consensus sequence for an intracellular antibody (ICS) comprising the steps of: creating a database comprising sequences of validated intracellular antibodies (VIDA database) and aligning the sequences of validated intracellular antibodies according to Kabat; determining the frequency with which a particular amino acid occurs in each of the positions of the aligned antibodies; selecting a frequency threshold value (LP or consensus threshold) in the range from 70% to 100%; identifying the positions of the alignment at which the frequency of a particular amino acid is greater than or equal to the LP value; and identifying the most frequent amino acid, in the position of said alignment.

Intracellular antibodies

A non-human transgenic animal that is transgenic for an antibody or fragments thereof and having a phenotype reminiscent of human pathology. The human pathology includes neurodegenerative syndromes, muscular atrophy/dystrophy and immune disorders. The animals may be used in a method for early diagnosis of neurodegenerative diseases. The method includes monitoring the occurrence of the tau hyperphosphorylation and/or amyloid deposition in the back or lower limb skeletal muscle sample of a subject. Cells are derivable from the non-human transgenic animal and secreting the transgenic antibody. The cells are used for the selection of molecules pharmacologically effective in neurodegenerative and/or muscular pathologies and/or immune disorders. A non-human transgenic animal may be prepared by providing a first non-human transgenic parent animal for the light chain of an antibody and a second non-human transgenic parent animal for the heavy chain of the same antibody, breeding the two transgenic parent animals and selecting the progeny expressing both the light and the heavy chain.

Non-human transgenic animals for the study of neurodegenerative syndromes

Growing community of inventors

Rome, Italy

Antonino Cattaneo